• Consensus Rating: Reduce
  • Consensus Price Target: $16.00
  • Forecasted Upside: -0.31%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$16.05
▲ +0.23 (1.45%)

This chart shows the closing price for ZIMV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ZimVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZIMV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZIMV

Analyst Price Target is $16.00
▼ -0.31% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for ZimVie in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a -0.31% upside from the last price of $16.05.

This chart shows the closing price for ZIMV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 3 polled investment analysts is to reduce stock in ZimVie. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/14/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/11/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2024Needham & Company LLCReiterated RatingHoldLow
3/5/2024BarclaysBoost TargetUnderweight ➝ Underweight$13.00 ➝ $16.00Low
1/4/2024BarclaysBoost TargetUnderweight ➝ Underweight$11.00 ➝ $13.00Low
12/20/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$10.00 ➝ $16.00Low
11/16/2023Needham & Company LLCInitiated CoverageHoldLow
11/2/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$15.00 ➝ $10.00Low
8/7/2023BarclaysBoost TargetUnderweight ➝ Underweight$7.00 ➝ $11.00Low
5/9/2023BarclaysBoost Target$5.00 ➝ $7.00Low
3/6/2023BarclaysLower TargetUnderweight$9.00 ➝ $5.00Low
12/21/2022BarclaysInitiated CoverageUnderweight$9.00Low
6/17/2022JPMorgan Chase & Co.Initiated CoverageNeutral$20.00Low
3/18/2022GuggenheimInitiated CoverageNeutralHigh
3/1/2022Credit Suisse GroupInitiated CoverageUnderperform$34.00Low
(Data available from 5/8/2019 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2023
  • 5 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/10/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/9/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/8/2024
  • 10 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/9/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

ZimVie logo
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Read More

Today's Range

Now: $16.05
Low: $15.69
High: $16.09

50 Day Range

MA: $16.48
Low: $15.20
High: $19.60

52 Week Range

Now: $16.05
Low: $6.52
High: $20.91

Volume

221,518 shs

Average Volume

225,294 shs

Market Capitalization

$436.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17

Frequently Asked Questions

What sell-side analysts currently cover shares of ZimVie?

The following equities research analysts have issued stock ratings on ZimVie in the last year: Barclays PLC, JPMorgan Chase & Co., and Needham & Company LLC.
View the latest analyst ratings for ZIMV.

What is the current price target for ZimVie?

2 Wall Street analysts have set twelve-month price targets for ZimVie in the last year. Their average twelve-month price target is $16.00, suggesting a possible downside of 0.3%. Barclays PLC has the highest price target set, predicting ZIMV will reach $16.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $16.00 for ZimVie in the next year.
View the latest price targets for ZIMV.

What is the current consensus analyst rating for ZimVie?

ZimVie currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for ZIMV.

What other companies compete with ZimVie?

How do I contact ZimVie's investor relations team?

The company's listed phone number is 303-443-7500 and its investor relations email address is [email protected]. The official website for ZimVie is www.zimvie.com. Learn More about contacing ZimVie investor relations.